Orthofix Medical (NASDAQ:OFIX) Releases Quarterly Earnings Results

Orthofix Medical (NASDAQ:OFIX - Get Free Report) posted its quarterly earnings results on Tuesday. The medical device company reported ($1.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($1.18), Zacks reports. The business had revenue of $193.65 million during the quarter, compared to analyst estimates of $191.10 million. Orthofix Medical had a negative net margin of 15.18% and a negative return on equity of 21.25%. Orthofix Medical updated its FY 2025 guidance to EPS.

Orthofix Medical Stock Performance

Shares of OFIX traded down $0.20 during mid-day trading on Friday, hitting $12.11. The company's stock had a trading volume of 568,612 shares, compared to its average volume of 259,233. The stock's 50-day moving average is $14.86 and its two-hundred day moving average is $16.91. The firm has a market capitalization of $472.56 million, a PE ratio of -3.87 and a beta of 0.87. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.11 and a current ratio of 2.39. Orthofix Medical has a one year low of $10.50 and a one year high of $20.73.

Insider Buying and Selling

In related news, insider Jorge Andres Cedron sold 3,816 shares of the firm's stock in a transaction on Wednesday, April 16th. The stock was sold at an average price of $13.31, for a total transaction of $50,790.96. Following the completion of the sale, the insider now directly owns 42,500 shares of the company's stock, valued at $565,675. This trade represents a 8.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Engine Capital Management, Lp acquired 100,000 shares of Orthofix Medical stock in a transaction on Wednesday, May 7th. The stock was acquired at an average cost of $12.31 per share, for a total transaction of $1,231,000.00. Following the purchase, the insider now owns 3,544,807 shares of the company's stock, valued at approximately $43,636,574.17. This represents a 2.90 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 8,475 shares of company stock valued at $128,065. 2.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on OFIX. StockNews.com lowered shares of Orthofix Medical from a "buy" rating to a "hold" rating in a research note on Wednesday. Roth Mkm reaffirmed a "buy" rating and issued a $22.00 price target on shares of Orthofix Medical in a report on Wednesday, February 26th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $24.00 price objective on shares of Orthofix Medical in a research note on Wednesday, February 26th.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.